Orexo
 | |
| Company type | Public |
|---|---|
| Nasdaq Stockholm: ORX OTCQX: ORXOY | |
| Industry | Pharmaceutical |
| Founded | 1995 |
| Headquarters | Uppsala, Sweden |
Area served | Worldwide |
Key people | Nikolaj Sørensen (CEO) |
| Products | See list |
| Revenue |  SEK 429.4 million (2013)[1] |
 SEK 154.9 million (2013)[1] | |
Number of employees | 108 (2013) [1] |
| Website | Orexo.com |
| Footnotes / references Employee and financial data as of 2014[update][needs update] | |
Orexo is a pharmaceutical company based in Uppsala, Sweden initially financed with venture capital provided by HealthCap.
The company was founded in 1995 and their first product Diabact UBT, a breath test for diagnosing the causative agent of stomach ulcers (Helicobacter pylori), was introduced in 2000.[2] In 2003, the company adopted the name Orexo and in 2005 the company was listed on the Stockholm Stock Exchange.[2]
Products
- Abstral, for the treatment of breakthrough cancer pain. It was approved in 2008 in Europe and for marketing in United States by the FDA in 2011.[2]
- Edluar, for the treatment of short-term insomnia. FDA approved in 2009.[2]
- Zubsolv a dissolvable tablet which combines the drugs buprenorphine and naloxone and treats opioid dependency and addiction.[3] FDA approved in July 2013.[3] Launched in the United States in September 2013 [4]
References
- ^ a b c "2013 Annual Report". Orexo. 2014. Retrieved October 12, 2014.
- ^ a b c d "History". Orexo. Retrieved July 5, 2013.
- ^ a b Toni Clarke (July 4, 2013). "U.S. FDA approves Orexo drug to treat opioid addiction". Reuters. Retrieved July 5, 2013.
- ^ Press releases - Orexo